Analyst Ratings for Health Management (HMA)
HMA Rating Summary
HMA Price Target Summary
- Highest: $14.50 (Jefferies)
- Lowest: $6.50 (CRT Capital)
- Average: $10.35
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$10.35 (-4.1%)
Avg. $ Target:
$10.35 (-4.1%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/10/2013 | Deutsche Bank | Downgrade | Hold (Buy) |
13.00 (N/A) |
12.59 | 10.79 | -14.3% | Details |
| 3/18/2013 | Jefferies | Upgrade | Buy (Hold) |
14.50 (N/A) |
12.26 | 10.79 | -11.99% | Details |
| 1/17/2013 | Morgan Stanley | New Coverage | Underweight (N/A) |
N/A (N/A) |
9.51 | 10.79 | 13.46% | Details |
| 1/9/2013 | Raymond James | Downgrade | Market Perform (Outperform) |
N/A (N/A) |
9.22 | 10.79 | 17.03% | Details |
| 12/18/2012 | JPMorgan | New Coverage | Neutral (N/A) |
9.00 (N/A) |
8.28 | 10.79 | 30.31% | Details |
| 12/14/2012 | Imperial Capital | Upgrade | Outperform (In-Line) |
N/A (N/A) |
8.11 | 10.79 | 33.05% | Details |
| 12/3/2012 | CRT Capital | Downgrade | Sell (Fairly Valued) |
6.50 (N/A) |
7.95 | 10.79 | 35.72% | Details |
| 11/26/2012 | Baird | Downgrade | Neutral (Outperform) |
N/A (N/A) |
8.23 | 10.79 | 31.11% | Details |
| 10/18/2012 | Avondale Partners | New Coverage | Market Outperform (N/A) |
9.20 (N/A) |
7.59 | 10.79 | 42.16% | Details |
| 10/11/2012 | Barclays | New Coverage | Equalweight (N/A) |
9.00 (N/A) |
7.66 | 10.79 | 40.86% | Details |
| 9/25/2012 | WallachBeth Capital | Downgrade | Hold (Buy) |
N/A (N/A) |
8.49 | 10.79 | 27.09% | Details |
| 7/18/2012 | Susquehanna | Downgrade | Neutral (Positive) |
N/A (N/A) |
7.71 | 10.79 | 39.95% | Details |
| 6/20/2012 | UBS | New Coverage | Buy (N/A) |
11.00 (N/A) |
6.81 | 10.79 | 58.44% | Details |
| 6/11/2012 | Citi | Upgrade | Buy (Neutral) |
N/A (N/A) |
6.55 | 10.79 | 64.73% | Details |
| 3/9/2012 | Cantor Fitzgerald | New Coverage | Hold (N/A) |
8.00 (N/A) |
6.85 | 10.79 | 57.52% | Details |
